Company / Operating Income
CytomX Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$22.4M
FY2025
5-year range
-$116.0M / $25.0M
FY2021-FY2025
Trend
-189.5%
vs FY2024
Sector context
#65 of 204
Health Care
What the data says
At -$22M, CytomX Therapeutics, Inc.'s operating income ranks #65 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$116M in FY2021 to $25M in FY2024.
Based on SEC 10-K filings.
-$22M in FY2025.
Declined from -$6M to -$22M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#65 of 204 in Health CareTop 32% of 204This company -$22.4M Sector average $107.7M
▼
-120.8% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 189.5% year-over-year.
- Ranks #65 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$22.4M | -189.5% |
| FY2024 | $25.0M | +485.5% |
| FY2023 | -$6.5M | +93.6% |
| FY2022 | -$101.3M | +12.7% |
| FY2021 | -$116.0M | -138.7% |
| FY2020 | -$48.6M | +56.2% |
| FY2019 | -$110.9M | -42.4% |
| FY2018 | -$77.9M | -68.3% |
| FY2017 | -$46.3M | +22.4% |
| FY2016 | -$59.6M | -298.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026